Loading
A phase 1 trial of Lunresertib run by Debiopharm International SA, terminated.
Study of RP-6306 With Gemcitabine in Advanced Solid Tumors is a phase 1 interventional study registered as NCT05147272 by Debiopharm International SA, with 67 participants enrolled, started 2021-12-16. Conditions recorded: Adult Solid Tumor. Interventions recorded: RP-6306 (oral PKMYT1 inhibitor).
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lunresertib, Repare Therapeutics, Debiopharm and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Repare Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Debiopharm and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/